Pharmacotherapy for smoking cessation: Present and future

Current Pharmaceutical Design

Volumn 17, Issue 14, 2011, Pages 1343-1350

  Aubin, Henri Jean ^a   Karila, Laurent ^a   Reynaud, Michel ^a  

^a Universite Paris Sud   (France)

Author keywords

Bupropion; Nicotine replacement therapy; Varenicline

Indexed keywords

AMFEBUTAMONE; BACLOFEN; CLONIDINE; CYCLOSERINE; CYTISINE; DOPAMINE 3 RECEPTOR BLOCKING AGENT; EVT 302; GABAPENTIN; GSK598809; GW 468816; MEMANTINE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NALMEFENE; NALTREXONE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NICOTINE VACCINE; NORTRIPTYLINE; PLACEBO; RIMONABANT; SURINABANT; TARANABANT; TOPIRAMATE; UNCLASSIFIED DRUG; VARENICLINE;

ABNORMAL DREAMING; ANGIONEUROTIC EDEMA; ANXIETY; APPLICATION SITE IRRITATION; COMORBIDITY; COUGHING; DEATH; DEPRESSION; DIZZINESS; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; FOOD AND DRUG ADMINISTRATION; HICCUP; HUMAN; IMMUNOTHERAPY; INSOMNIA; JAW PAIN; MOUTH SORENESS; NAUSEA; NAUSEA AND VOMITING; NICOTINE REPLACEMENT THERAPY; NONHUMAN; NOSE IRRITATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RHINORRHEA; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; SMOKING CESSATION; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; THROAT IRRITATION; TOBACCO DEPENDENCE; TRANSDERMAL PATCH; TREMOR; UNSPECIFIED SIDE EFFECT; URTICARIA; XEROSTOMIA;

ADOLESCENT; ANIMALS; BENZAZEPINES; BUPROPION; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; NICOTINE; NICOTINIC AGONISTS; PREGNANCY; QUINOXALINES; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 79959985056     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796150837     Document Type: Review

References (125)

1. Doll R, Hill AB. Smoking and carcinoma of the lung; preliminary report. Br Med J 1950; 2: 739-48.
2. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years'observation on male british doctors. British Medical Journal 2004: 1-9
3. Bjartveit K, Tverdal A. Health consequences of sustained smoking cessation. Tob Control 2009; 18(3): 197-205.
4. U.S. Department of Health and Human Services. The health consequences of smoking: nicotine addiction: a report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Health Promotion and Education, Office on Smoking and Health; 1988 [cited 2010 October 1]; Available from: http://profiles.nlm.nih.gov/NN/B/B/Z/D/_/nnbbzd.pdf.
5. Fiore MC, Jaén CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; 2008 [updated May 2008; cited 2010 October 1]; Available from: http://www.ncbi.nlm.nih.gov.gate2.inist.fr/books/NBK12193/.
6. Centers for Disease Control and Prevention (CDC). Annual smoking-attributable mortality, years of potential life lost, and productivity losses-United States, 1997-2001. MMWR Morb Mortal Wkly Rep 2005; 54: 625-8.
7. The Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel L, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med 2008; 35(2): 158-76.
8. Jha P. Avoidable global cancer deaths and total deaths from smoking. Nat Rev Cancer 2009; 9(9): 655-64
9. Benowitz NL. Nicotine addiction. N Engl J Med 2010; 362(24): 2295-303.
10. Shiffman S, Scharf DM, Shadel WG, et al. Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers. J Consult Clin Psychol 2006; 74(2): 276-85.
11. Benowitz NL. Pharmacology of Nicotine: Addiction, Smoking- Induced Disease, and Therapeutics. Annu Rev Pharmacol Toxicol 2008 Oct 3.
12. Benowitz NL, Porchet H, Sheiner L, Jacob P, 3rd. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther 1988; 44(1): 23-8.
13. Rose JE, Behm FM, Westman EC, Coleman RE. Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: implications for addiction. Drug Alcohol Depend 1999; 56(2): 99-107.
14. Picciotto MR, Zoli M, Rimondini R, et al. Acetylcholine receptors containing the β 2 subunit are involved in the reinforcing properties of nicotine. Nature 1998; 391: 173-7.
15. Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996; 382(6588): 255-7.
16. Nisell M, Nomikos GG, Svensson TH. Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 1994; 16(1): 36-44.
17. Tisch S, Silberstein P, Limousin-Dowsey P, Jahanshahi M. The basal ganglia: anatomy, physiology, and pharmacology. Psychiatr Clin North Am 2004; 27: 757-99.
18. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 2000; 393: 295-314.
19. Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev 2008 (2): CD000165.
20. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005(2): CD001292.
21. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007(1): CD000031.
22. Edens E, Massa A, Petrakis I. Novel pharmacological approaches to drug abuse treatment. Curr Top Behav Neurosci 2010; 3: 343-86.
23. Fant RV, Buchhalter AR, Buchman AC, Henningfield JE. Pharmacotherapy for tobacco dependence. Handb Exp Pharmacol 2009(192): 487-510.
24. George TP, Weinberger AH. Monoamine oxidase inhibition for tobacco pharmacotherapy. Clin Pharmacol Ther 2008; 83(4): 619- 21.
25. Berlin I, Saïd S, Spreux-Varoquaux O, Olivares R, Launay JM, Puech AJ. Monoamine oxidase A and B activities in heavy smokers. Biological Psychiatry 1995; 38: 756-61.
26. West RJ, Jarvis MJ, Russell MA, Carruthers ME, Feyerabend C. Effect of nicotine replacement on the cigarette withdrawal syndrome. Br J Addict 1984; 79(2): 215-9.
27. Foulds J, Burke M, Steinberg M, Ziedonis DM, Williams JM. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs 2004; 9(1): 39-53.
28. Buchhalter AR, Fant RV, Henningfield JE. Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs 2008; 68(8): 1067-88.
29. Nides M. Update on pharmacologic options for smoking cessation treatment. Am J Med 2008; 121(4 Suppl 1): S20-31.
30. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008(1): CD000146.
31. Sweeney CT, Fant RV, Fagerstrom KO, McGovern JF, Henningfield JE. Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs 2001; 15(6): 453-67.
32. Parsons AC, Shraim M, Inglis J, Aveyard P, Hajek P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev 2009(1): CD006219.
33. Bullen C, Howe C, Lin RB, Grigg M, Laugesen M, McRobbie H, et al. Pre-cessation nicotine replacement therapy: pragmatic randomized trial. Addiction 2010 Jun 7.
34. Shiffman S, Ferguson SG. Nicotine patch therapy prior to quitting smoking: a meta-analysis. Addiction 2008; 103(4): 557-63.
35. Aubin HJ, Luthringer R, Demazieres A, Dupont C, Lagrue G. Comparison of the effects of a 24-hour nicotine patch and a 16- hour nicotine patch on smoking urges and sleep. Nicotine Tob Res 2006; 8(2): 193-201.
36. Staner L, Luthringer R, Dupont C, Aubin HJ, Lagrue G. Sleep effects of a 24-h versus a 16-h nicotine patch: a polysomnographic study during smoking cessation. Sleep Med 2006; 7(2): 147-54.
37. Etter JF. Addiction to the nicotine gum in never smokers. BMC Public Health 2007; 7: 159.
38. Etter JF. Dependence on the nicotine gum in former smokers. Addict Behav 2009; 34(3): 246-51.
39. Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chron Obstruct Pulmon Dis 2008; 3(1): 45-53.
40. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. Journal Clinical Psychiatry 1995; 56(9): 395-401.
41. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. The Journal of Pharmacology and Experimental Therapeutics 2000; 295: 321-7.
42. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane database of systematic reviews 2007(1): CD000031.
43. Mooney ME, Sofuoglu M. Bupropion for the treatment of nicotine withdrawal and craving. Expert Revneurotherapeutics 2006; 6(7): 965-81.
44. Gonzales D, Bjornson W, Durcan MJ, et al. Effects of gender on relapse prevention in smokers treated with bupropion SR. Am J Prev Med 2002; 22(4): 234-9.
45. Aubin HJ, Lebargy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebocontrolled trial. Addiction 2004; 99(9): 1206-18.
46. Aubin HJ. Tolerability and safety of sustained-release bupropion in the management of smoking cessation. Drugs 2002; 62 Suppl 2: 45-52.
47. Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003; 24(10): 946-55.
48. Tonstad S, Rollema H. Varenicline in smoking cessation. Expert Rev Respir Med 2010; 4(3): 291-9.
49. Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007; 52 985-94.
50. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an gamma4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA 2006; 296(1): 47-55.
51. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA 2006; 296(1): 56-63.
52. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist. Archives of Internal Medicine 2006; 166: 1561-8.
53. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Archives of Internal Medicine 2006; 166: 1571-7.
54. Niaura R, Hays JT, Jorenby DE, et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin 2008 May 29.
55. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2010; 12: CD006103.
56. Nides M, Glover ED, Reus VI, et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav 2008; 32(6): 664-75.
57. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008; 63(8): 717-24.
58. Stapleton J, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2007: 1-9.
59. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with Varenicline on smoking cessation. JAMA 2006; 296(1): 64-71.
60. Ebbert JO, Burke MV, Hays JT, Hurt RD. Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res 2009 Apr 7.
61. Ebbert JO, Croghan IT, Sood A, Schroeder DR, Hays JT, Hurt RD. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res 2009 Feb 25.
62. Cahill K, Stead L, Lancaster T. A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Saf 2009; 32(2): 119-35.
63. Ebbert JO, Wyatt KD, Hays JT, Klee EW, Hurt RD. Varenicline for smoking cessation: efficacy, safety, and treatment recommendations. Patient Prefer Adherence 2010; 4: 355-62.
64. Potts LA, Garwood CL. Varenicline: the newest agent for smoking cessation. Am J Health Syst Pharm 2007; 64(13): 1381-4.
65. U.S. Food and Drug Administration. Early communication about an ongoing safety review: varenicline (marketed as Chantix). Rockville, MD: U.S. Department of Health and Human Services; 2007 [updated November 20, 2007; cited 2010 October 1]; Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPa tientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070 765.htm.
66. U.S. Food and Drug Administration. Public health advisory: important information on Chantix (varenicline). Rockville, MD: U.S. Department of Health and Human Services; 2008 [updated February 1, 2008; cited 2010 October 1]; Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPa tientsandProviders/DrugSafetyInformationforHeathcareProfessionals/Public HealthAdvisories/ucm051136.htm.
67. U.S. Food and Drug Administration. Information for healthcare professionals: varenicline (marketed as Chantix) and bupropion (marketed as Zyban, Wellbutrin, and generics). Rockville, MD: U.S. Department of Health and Human Services; 2009 [updated July 1, 2009; cited 2010 October 1]; Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPa tientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm169 986.htm.
68. FDA. The smoking cessation aids varenicline (marketed as Chantix) and bupropion (marketed as Zyban and generics): suicidal ideation and behavior. FDA Drug Safety Newsletter Vol 2(1). 2009 [updated 2009; cited 2010 October 1]; Available from: http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm110235.htm.
69. Tonstad S, Davies S, Flammer M, Russ C, Hughes J. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf 2010; 33(4): 289-301.
70. Garza D, Murphy M, Tseng LJ, Riordan HJ, Chatterjee A. A Double-Blind Randomized Placebo-Controlled Pilot Study of Neuropsychiatric Adverse Events in Abstinent Smokers Treated with Varenicline or Placebo. Biol Psychiatry 2011 Feb 2.
71. Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009; 339: b3805.
72. Lising-Enriquez K, George TP. Treatment of comorbid tobacco use in people with serious mental illness. J Psychiatry Neurosci 2009; 34(3): E1-2.
73. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: A population-based prevalence study. JAMA 2000; 284(20): 2606-10.
74. Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. The American journal on addictions/American Academy of Psychiatrists in Alcoholism and Addictions 2005; 14(2): 106-23.
75. McCreadie RG. Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study. Br J Psychiatry 2002; 181: 321- 5.
76. Williams JM, Ziedonis D. Addressing tobacco among individuals with a mental illness or an addiction. Addictive behaviors 2004; 29(6): 1067-83.
77. Aubin HJ. Management of emergent psychiatric symptoms during smoking cessation. Curr Med Res Opin 2009; 25(2): 519-25.
78. Siru R, Hulse GK, Tait RJ. Assessing motivation to quit smoking in people with mental illness: a review. Addiction 2009; 104(5): 719- 33.
79. Fagerstrom K, Aubin HJ. Management of smoking cessation in patients with psychiatric disorders. Curr Med Res Opin 2009; 25(2): 511-8.
80. George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermalpatch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000; 157(11): 1835-42.
81. Tsoi DT, Porwal M, Webster AC. Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2010; 196(5): 346-53.
82. McClure JB, Swan GE, Catz SL, et al. Smoking outcome by psychiatric history after behavioral and varenicline treatment. JSubst Abuse Treat 2010 Apr 1.
83. Kinnunen T, Doherty K, Militello FS, Garvey AJ. Depression and smoking cessation: characteristics of depressed smokers and effects of nicotine replacement. J Consult Clin Psychol 1996; 64(4): 791-8.
84. Herman AI, Sofuoglu M. Comparison of Available Treatments for Tobacco Addiction. Curr Psychiatry Rep 2010 Jul 10.
85. Grange G, Vayssiere C, Borgne A, et al. Description of tobacco addiction in pregnant women. Eur J Obstet Gynecol Reprod Biol 2005; 120(2): 146-151.
86. Oncken CA, Kranzler HR. What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy? Nicotine Tob Res 2009; 11(11): 1265-73.
87. Chan B, Einarson A, Koren G. Effectiveness of bupropion for smoking cessation during pregnancy. J Addict Dis 2005; 24(2): 19-23.
88. Chun-Fai-Chan B, Koren G, Fayez I, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005; 192(3): 932-6.
89. Bronisch T, Hofler M, Lieb R. Smoking predicts suicidality: findings from a prospective community study. J Affect Disord 2008; 108(1-2): 135-145.
90. Kim Y, Myung SK, Jeon YJ, et al. Effectiveness of pharmacologic therapy for smoking cessation in adolescent smokers: Metaanalysis of randomized controlled trials. Am J Health Syst Pharm 2011; 68(3): 219-26.
91. D'Orlando KJ, Fox BS. Tolerability and pharmacokinetics of single and repeated doses of nicotine with The Straw, a novel nicotine replacement product. Nicotine Tob Res 2004; 6(1): 63-70.
92. Westman EC, Tomlin KF, Perkins CE, Rose JE. Oral nicotine solution for smoking cessation: a pilot tolerability study. Nicotine Tob Res 2001; 3(4): 391-6.
93. Etter JF. Cytisine for smoking cessation. Archives of Internal Medicine 2006; 166: 1553-9.
94. Tutka P, Zatonski W. Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic effcacy. Pharmacological reports 2005; 58: 777-98.
95. Tonstad S, Holme I, Tonnesen P. Dianicline, a Novel {alpha}4{beta}2 Nicotinic Acetylcholine Receptor Partial Agonist, for Smoking Cessation: A Randomized Placebo-Controlled Clinical Trial. Nicotine Tob Res 2010 Nov 1.
96. Lancaster T, Stead L, Cahill K. An update on therapeutics for tobacco dependence. Expert Opin Pharmacother 2008; 9(1): 15-22.
97. George TP, O'Malley SS. Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 2004; 25(1): 42-8.
98. Spring B, Doran N, Pagoto S, et al. Fluoxetine, smoking, and history of major depression: A randomized controlled trial. J Consult Clin Psychol 2007; 75(1): 85-94.
99. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev 2008 (3): CD000058.
100. Berlin I, Anthenelli RM. Monoamine oxidase and tobacco smoking. Journal of Neuropsychopharmacology 2001; 4: 33-42.
101. Berlin I, Said S, Spreux-Varoquaux O, et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther 1995; 58(4): 444-52.
102. Berlin I, Aubin HJ, Pedarriosse AM, Rames A, Lancrenon S, Lagrue G. Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation. Addiction 2002; 97(10): 1347-54.
103. Weinberger AH, Reutenauer EL, Jatlow PI, O'Malley SS, Potenza MN, George TP. A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. Drug Alcohol Depend 2010; 107(2-3): 188-95.
104. Cerny EH, Cerny T. Vaccines against nicotine. Hum Vaccin 2009; 5(4): 200-5.
105. Fagerstrom K, Balfour DJ. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opin Investig Drugs 2006; 15(2): 107-16.
106. Moreno AY, Janda KD. Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence. Pharmacol Biochem Behav 2009; 92(2): 199-205.
107. Le Foll B, Forget B, Aubin HJ, Goldberg SR. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addict Biol 2008; 13(2): 239-52.
108. Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev 2007(4): CD005353.
109. Morrison MF, Ceesay P, Gantz I, Kaufman KD, Lines CR. Randomized, controlled, double-blind trial of taranabant for smoking cessation. Psychopharmacology (Berl) 2010; 209(3): 245-253.
110. Baltieri DA, Daro FR, Ribeiro PL, Andrade AG. Effects of topiramate or naltrexone on tobacco use among male alcoholdependent outpatients. Drug Alcohol Depend 2009 Jul 10.
111. O'Malley SS, Cooney JL, Krishnan-Sarin S, et al. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch Intern Med 2006; 27; 166(6): 667-674.
112. Jackson A, Nesic J, Groombridge C, Clowry O, Rusted J, Duka T. Differential involvement of glutamatergic mechanisms in the cognitive and subjective effects of smoking. Neuropsychopharmacology 2009; 34(2): 257-65.
113. Shinn AK, Greenfield SF. Topiramate in the treatment of substance-related disorders: a critical review of the literature. J Clin Psychiatry 2010; 71(5): 634-48.
114. Anthenelli RM, Blom TJ, McElroy SL, Keck PE, Jr. Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation. Addiction 2008; 103(4): 687-94.
115. Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcoholdependent smokers. Archives of Internal Medicine 2005; 165: 1600-5.
116. Franklin TR, Harper D, Kampman K, et al. The GABA B agonist baclofen reduces cigarette consumption in a preliminary doubleblind placebo-controlled smoking reduction study. Drug Alcohol Depend 2009; 103(1-2): 30-6.
117. White WD, Crockford D, Patten S, El-Guebaly N. A randomized, open-label pilot comparison of gabapentin and bupropion SR for smoking cessation. Nicotine Tob Res 2005; 7(5): 809-13.
118. Sood A, Ebbert JO, Wyatt KD, et al. Gabapentin for smoking cessation. Nicotine Tob Res 2010; 12(3): 300-4.
119. Sood A, Ebbert JO, Schroeder DR, et al. Gabapentin for smoking cessation: a preliminary investigation of efficacy. Nicotine Tob Res 2007; 9(2): 291-8.
120. Ballon JS, Feifel D. A systematic review of modafinil: Potential clinical uses and mechanisms of action. J Clin Psychiatry 2006; 67(4): 554-66.
121. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005; 30(1): 205-11.
122. Lerman C, Roth D, Kaufmann V, et al. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend 2002; 67(2): 219-23.
123. Schnoll RA, Wileyto EP, Pinto A, et al. A placebo-controlled trial of modafinil for nicotine dependence. Drug Alcohol Depend 2008; 98(1-2): 86-93.
124. Le Foll B, Sokoloff P, Stark H, Goldberg SR. Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminativestimulus or antidepressant-like effects. Neuropsychopharmacology 2005; 30(4): 720-30.
125. Pollock JD, Koustova E, Hoffman A, Shurtleff D, Volkow ND. Treatments for nicotine addiction should be a top priority. Lancet 2009 Apr 24.